On January 14, 2026, Xingtai Technology made an announcement stating that its incubated company, ReviR Biotechnology, has successfully secured clinical trial approvals (known as IND approvals) for its innovative drug candidate, RTX - 117, in both China and the United States.

This significant milestone, coupled with several collaborative achievements, means that Xingtai Technology will be entitled to milestone payments amounting to tens of millions of Hong Kong dollars from ReviR.

ReviR is set to forge ahead with the subsequent phases of clinical development for RTX - 117. Meanwhile, Xingtai Technology will retain the rights to partake in sales royalties and share in the subsequent licensing revenue generated from this drug pipeline.

RTX - 117 holds a special place as it is the first domestically developed Class 1 innovative drug specifically designed to target Charcot - Marie - Tooth disease (CMT). Moreover, it stands as the only CMT drug currently available in China that intervenes in the disease process at its molecular root by targeting disease - related pathological pathways.

It is anticipated that this drug will break the long - standing impasse of a lack of effective treatment options for CMT and open up access to a potential global treatment market valued at over US$10 billion.